Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials
NEJM Evidence · 26.03.2024 · 3 (4)
DOI: 10.1056/evidoa2300236 ↗Kurz gefasst
Fachartikel in der Zeitschrift NEJM Evidence, erschienen am 26.03.2024. Verfasst von Maneet Kaur und 11 weiteren Autor:innen. Beteiligte Einrichtung: Flatiron Health, New York. Hauptthemen laut MEDLINE: Neoplasms, Patient Selection, Clinical Trials as Topic, Eligibility Determination. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Flatiron Health, New York.
- School of Public Health, Division of Health Policy and Management, University of California, Berkeley, Berkeley.
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia.
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland.
- Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC.
Zitieren
APA
Kaur, M., Frahm, F., Lu, Y., Ascha, M. S., Guadamuz, J. S., Dotan, E., Gottesman, A. S., Leybovich, B. C., Sondhi, A., Zhao, Y., Meropol, N. J., & Royce, T. J. (2024). Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials. NEJM Evidence, 3(4). https://doi.org/10.1056/evidoa2300236
Vancouver
Kaur M, Frahm F, Lu Y, Ascha MS, Guadamuz JS, Dotan E, et al. Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials. NEJM Evidence. 2024;3(4). doi:10.1056/evidoa2300236
BibTeX
@article{Kaur2024,
author = {Kaur, Maneet and Frahm, Filip and Lu, Yichen and Ascha, Mustafa S and Guadamuz, Jenny S and Dotan, Efrat and Gottesman, Adam S and Leybovich, Barry C and Sondhi, Arjun and Zhao, Yihua and Meropol, Neal J and Royce, Trevor J},
title = {Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials},
journal = {NEJM Evidence},
year = {2024},
volume = {3},
number = {4},
doi = {10.1056/evidoa2300236}
}
EUVIMED